Associated tags: Lung, Patient, COVID-19, Intelligence, Diagnosis, Malignancy, Artificial intelligence, Blood, Lung cancer, Physician, Biotechnology, Risk assessment, Triage, Health, Oncology, General Health, Research, Science, Pharmaceutical industry, Artificial Intelligence, Health Technology, Pharmaceutical
Locations: SOUTH CAROLINA, SINGAPORE, MASSACHUSETTS, NY, HAWAII, NET, UNITED STATES, NORTH AMERICA, CALIFORNIA, COLORADO, TD, USA, CHICAGO, NEW YORK
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences:
Key Points:
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences:
Data Management,
Medical Supplies,
Practice Management,
Other Science,
Technology,
FDA,
Research,
General Health,
Other Health,
Radiology,
Pharmaceutical,
Oncology,
Medical Devices,
Hospitals,
Genetics,
Clinical Trials,
Artificial Intelligence,
Biotechnology,
Software,
Health,
Science,
Patient,
University,
FCCP,
Conference,
MSC,
American Thoracic Society,
Emphysema,
Lung cancer,
Associate,
ATS,
Critical Care Medicine (journal),
Quality of life,
Medical device Emphysema is a common comorbid pulmonary condition in patients with lung nodules and presents unique diagnostic and treatment challenges.
Key Points:
- Emphysema is a common comorbid pulmonary condition in patients with lung nodules and presents unique diagnostic and treatment challenges.
- These results suggest that the test can assist with ruling out lung cancer regardless of a patient’s emphysema status.
- "During the course of emphysema treatment, many of our patients present with suspicious lung nodules," said Dr. Romero.
- Some nodules need to be followed for up to two years to establish stability, but many patients cannot wait this long.
Radiology,
Pharmaceutical,
Research,
Oncology,
Software,
Medical Devices,
Hospitals,
Genetics,
Data Management,
Stem Cells,
Science,
Practice Management,
Technology,
Clinical Trials,
Medical Supplies,
FDA,
Biotechnology,
Surgery,
Health,
CO,
Cancer,
Depreciation,
Webcast,
DdPCR,
Forecasting,
Growth,
MSKCC,
Net operating loss,
Patient,
COVID-19,
Acquisition,
Adjustment,
AACR,
Bank statement,
EGFR,
GAAP,
AstraZeneca In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
Key Points:
- In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
- Our team is off to a strong start, helping to impact more patients every quarter in the large and underserved lung nodule diagnostic testing market.
- Record quarterly gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023.
- The Company reaffirms its 2024 financial outlook and expects to generate between $65 million and $68 million in total revenue in 2024.
Other Health,
Software,
General Health,
Pharmaceutical,
Oncology,
Technology,
Artificial Intelligence,
Health Technology,
Clinical Trials,
Cardiology,
Biotechnology,
Health,
Conference Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024.
Key Points:
- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024.
Retrieved on:
Wednesday, April 24, 2024
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8.
Key Points:
- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8.
- Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
- Analysts who wish to participate in the question and answer session should use this link .
- A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion.
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Artificial Intelligence,
Technology,
Nucleic acid thermodynamics,
Trial of the century,
Plasma,
DdPCR,
Digital,
DNA,
Patient,
AACR,
EGFR,
NSCLC,
AstraZeneca,
Liquid biopsy,
Medical imaging Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
Key Points:
- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
- These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical setting.
- Biodesix supported this research by providing the EGFRm testing using Droplet Digital™ PCR* (ddPCR™) on plasma samples collected prior to treatment and three and six weeks after treatment initiation.
- EGFRm testing is offered in a clinical setting by Biodesix as part of the GeneStrat® ddPCR targeted mutation test.
Biotechnology,
Technology,
Health,
General Health,
Pharmaceutical,
Health Technology,
Other Science,
Research,
Artificial Intelligence,
Science,
Clinical Trials,
Vanderbilt Avenue,
Canaccord Genuity,
Form,
Telephone,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Suite,
Form S-3 Subject to Biodesix stockholder approval, each share of Series A Non-Voting Convertible Preferred Stock will automatically convert to 40 shares of common stock for an aggregate of 30,434,280 shares of common stock.
Key Points:
- Subject to Biodesix stockholder approval, each share of Series A Non-Voting Convertible Preferred Stock will automatically convert to 40 shares of common stock for an aggregate of 30,434,280 shares of common stock.
- The gross proceeds to Biodesix from the underwritten offering and concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering expenses payable by Biodesix, and following the receipt of stockholder approval, are expected to be $55.0 million.
- TD Cowen, William Blair and Canaccord Genuity are acting as joint bookrunning managers for the underwritten offering and placement agents for the concurrent private placement.
- Lake Street Capital Markets is acting as lead manager for the underwritten offering and placement agent for the concurrent private placement.
Science,
Biotechnology,
Research,
Oncology,
Health,
Medical Devices,
Health Technology,
Genetics,
PCR,
Genomics,
EVP,
International,
Biomarker,
Cancer,
Proteomics,
MCRA,
Bio-Rad Laboratories,
MSRA,
MSK Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.
Key Points:
- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.
- Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK .
- “The expansion of our previous master sponsored research agreement (MSRA) into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics.
- Biodesix looks forward to co-developing and validating new test concepts under these agreements,” said Scott Hutton, CEO, Biodesix.
Biotechnology,
Pharmaceutical,
Oncology,
Health,
Artificial Intelligence,
Health Technology,
Technology,
Other Health,
Total,
Forecasting,
Marketing,
Growth,
COVID-19 testing,
GAAP,
COVID-19,
Webcast,
COVID,
Patient,
Lung cancer,
Bank statement,
Net operating loss,
Research,
Depreciation,
Pharmaceutical industry Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).
Key Points:
- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).
- “I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023,” said Scott Hutton, CEO of Biodesix.
- I am very pleased with our significant progress on each of these goals.”
Mr. Hutton continued, “The Biodesix team delivered 65% growth in Lung Diagnostic test volume for the full year 2023 and a sixth straight quarter of over 50% year-over-year growth, with the fourth quarter FY23 growing 54% over the fourth quarter of FY22.
- Biodesix reported results are presented in accordance with generally accepted accounting principles in the United States (GAAP).
Retrieved on:
Monday, February 26, 2024
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024.
Key Points:
- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024.
